Novo Nordisk’s oral Wegovy drives Q1 revenue surge 24% to DKK 96.8B; stock still 44% off high. Key CagriSema phase 3 data at ADA conference in June may restore pipeline confidence.<\/p>\n
The Danish pharma giant has been fighting a two-front war: a punishing share price slide and the relentless advance of competitors. Yet beneath the surface, the oral version of Wegovy is quietly reshaping the narrative. Since its US debut on 5 January 2026, the pill has racked up over 2 million prescriptions \u2014 1.3 million of those in the first quarter alone. By the week ending 17 April, weekly scripts had breached 200,000, a launch velocity that dwarfs earlier GLP-1 entries in the American market. That momentum has translated into hard numbers: first-quarter revenue jumped 24% to DKK 96.8 billion, while profit surged 67%. Management promptly lifted its full-year guidance.<\/p>\n
But the stock remains deeply scarred. At roughly DKK 293 (\u20ac39.33 or $45.57), it still sits 44% below its 52-week high. Over the past 30 days, however, a 13% recovery suggests investors are sniffing a bargain. The price-to-earnings ratio of about 11 looks historically cheap, and the dividend yield has swelled to 3.84%. Analysts characterise the period as a “transition year”, with pricing pressure in the US and doubts about the pipeline’s competitive edge capping any exuberance.<\/p>\n
The next major test begins on 5 June in New Orleans, where Novo Nordisk will present 40 abstracts at the American Diabetes Association’s Scientific Sessions. The spotlight falls squarely on CagriSema, a fixed-dose combination of semaglutide and the long-acting amylin analogue cagrilintide. Phase 3 data from the REIMAGINE-1, -2 and -3 studies in type-2 diabetes will be unveiled, along with phase 2 results for Zenagamtide, an experimental once-weekly GLP-1\/amylin injectable that forms part of the company’s strategy to branch beyond the semaglutide franchise. Updated cardiometabolic profiles for Ozempic and Wegovy are also on the slate.<\/p>\n